{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:51:31Z","timestamp":1789069891298,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Office of National Higher Education Science Research and Innovation Policy Council by Program Management Unit for Human Resources and Institutional Development, Research and Innovation","award":["B05F640067"],"award-info":[{"award-number":["B05F640067"]}]},{"name":"Thailand Science Research and Innovation Fund Chulalongkorn University","award":["HEA663700097"],"award-info":[{"award-number":["HEA663700097"]}]},{"name":"The 90th Anniversary Chulalongkorn University Fund","award":["GCUGR1125662073M"],"award-info":[{"award-number":["GCUGR1125662073M"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90997-y","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:42:01Z","timestamp":1740505321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CDK4\/6 inhibitors upregulate cIAP1\/2, and Smac mimetic LCL161 enhances their antitumor effects in cholangiocarcinoma cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Pimchanok","family":"Menapree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaya","family":"Duangthim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apiwit","family":"Sae-Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasiprapa","family":"Sonkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn","family":"Jitkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"9","key":"90997_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Reviews Gastroenterol. Hepatol. 17 (9), 557\u2013588 (2020).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"issue":"1","key":"90997_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12876-016-0565-6","volume":"17","author":"S Treeprasertsuk","year":"2017","unstructured":"Treeprasertsuk, S. et al. A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study. BMC Gastroenterol. 17 (1), 3 (2017).","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"90997_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bpg.2015.02.001","volume":"29","author":"RR Plentz","year":"2015","unstructured":"Plentz, R. R. & Malek, N. P. Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol. 29 (2), 245\u2013252 (2015).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"11","key":"90997_CR4","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.7314\/APJCP.2012.14.11.7029","volume":"14","author":"N Thunyaharn","year":"2013","unstructured":"Thunyaharn, N., Promthet, S., Wiangnon, S., Suwanrungruang, K. & Kamsa-ard, S. Survival of cholangiocarcinoma patients in Northeastern Thailand after supportive treatment. Asian Pac. J. Cancer Prev. 14 (11), 7029\u20137032 (2013).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"90997_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15 (2), 95\u2013111 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"90997_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas, S. I. et al. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat. Rev. Clin. Oncol. 20 (7), 470\u2013486 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5\u20136","key":"90997_CR7","first-page":"155","volume":"4","author":"KR Eckmann","year":"2011","unstructured":"Eckmann, K. R. et al. Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis. Gastrointest. Cancer Res. 4 (5\u20136), 155\u2013160 (2011).","journal-title":"Gastrointest. Cancer Res."},{"issue":"1","key":"90997_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12 (1), 31\u201346 (2022).","journal-title":"Cancer Discov"},{"issue":"6","key":"90997_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","volume":"39","author":"JM Suski","year":"2021","unstructured":"Suski, J. M., Braun, M., Strmiska, V. & Sicinski, P. Targeting cell-cycle machinery in cancer. Cancer Cell. 39 (6), 759\u2013778 (2021).","journal-title":"Cancer Cell."},{"issue":"11","key":"90997_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (11), 1770\u20131783 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"90997_CR11","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/hep.30704","volume":"70","author":"G Sittithumcharee","year":"2019","unstructured":"Sittithumcharee, G. et al. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology 70 (5), 1614\u20131630 (2019).","journal-title":"Hepatology"},{"issue":"1","key":"90997_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 40 (1), 70\u201387e15 (2022).","journal-title":"Cancer Cell."},{"issue":"4","key":"90997_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia, D. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144 (4), 829\u2013840 (2013).","journal-title":"Gastroenterology"},{"issue":"4","key":"90997_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6 (4), 353\u2013367 (2016).","journal-title":"Cancer Discov"},{"issue":"3","key":"90997_CR15","first-page":"901","volume":"39","author":"M Liu","year":"2018","unstructured":"Liu, M., Liu, H. & Chen, J. Mechanisms of the CDK4\/6 inhibitor Palbociclib (PD 0332991) and its future application in cancer treatment (review). Oncol. Rep. 39 (3), 901\u2013911 (2018).","journal-title":"Oncol. Rep."},{"issue":"21","key":"90997_CR16","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver, J. A. et al. FDA approval: Palbociclib for the treatment of postmenopausal patients with Estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res. 21 (21), 4760\u20134766 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"90997_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn, R. S., Aleshin, A. & Slamon, D. J. Targeting the cyclin-dependent kinases (CDK) 4\/6 in Estrogen receptor-positive breast cancers. Breast Cancer Res. 18 (1), 17 (2016).","journal-title":"Breast Cancer Res."},{"issue":"20","key":"90997_CR18","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","volume":"22","author":"AJ Walker","year":"2016","unstructured":"Walker, A. J. et al. FDA approval of Palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin. Cancer Res. 22 (20), 4968\u20134972 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"90997_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel, S., DeCristo, M. J., McAllister, S. S. & Zhao, J. J. CDK4\/6 Inhibition in cancer: beyond cell cycle arrest. Trends Cell. Biol. 28 (11), 911\u2013925 (2018).","journal-title":"Trends Cell. Biol."},{"key":"90997_CR20","doi-asserted-by":"crossref","unstructured":"Huang, J., Zheng, L., Sun, Z. & Li, J. CDK4\/6 inhibitor resistance mechanisms and treatment strategies (review). Int. J. Mol. Med. 50 (4). (2022).","DOI":"10.3892\/ijmm.2022.5184"},{"issue":"1","key":"90997_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","volume":"34","author":"ME Klein","year":"2018","unstructured":"Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D. & Koff, A. CDK4\/6 inhibitors: the mechanism of action May not be as simple as once thought. Cancer Cell 34 (1), 9\u201320 (2018).","journal-title":"Cancer Cell."},{"key":"90997_CR22","doi-asserted-by":"crossref","unstructured":"Li, Z. et al. Mechanisms of CDK4\/6 inhibitor resistance in luminal breast cancer. Front. Pharmacol. 11. (2020).","DOI":"10.3389\/fphar.2020.580251"},{"issue":"2","key":"90997_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","volume":"42","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies. Acta Pharmacol. Sin. 42 (2), 171\u2013178 (2021).","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"90997_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell. Chem. Biol. 26 (8), 1067\u201380e8 (2019).","journal-title":"Cell. Chem. Biol."},{"issue":"1","key":"90997_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin, X. et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-\u03baB activation and PD-L1 expression. Mol. Cell 73 (1), 22\u201335e6 (2019).","journal-title":"Mol. Cell."},{"issue":"8","key":"90997_CR26","doi-asserted-by":"publisher","first-page":"e106056","DOI":"10.1371\/journal.pone.0106056","volume":"9","author":"W Seubwai","year":"2014","unstructured":"Seubwai, W. et al. Aberrant expression of NF-\u03baB in liver fluke associated cholangiocarcinoma: implications for targeted therapy. PLoS One  9 (8), e106056 (2014).","journal-title":"PLOS ONE"},{"issue":"8","key":"90997_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrc2889","volume":"10","author":"M Gyrd-Hansen","year":"2010","unstructured":"Gyrd-Hansen, M. & Meier, P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer  10 (8), 561\u2013574 (2010).","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"90997_CR28","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","volume":"21","author":"S Fulda","year":"2015","unstructured":"Fulda, S. Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res. 21 (22), 5030\u20135036 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"90997_CR29","doi-asserted-by":"publisher","first-page":"e0227454","DOI":"10.1371\/journal.pone.0227454","volume":"15","author":"P Akara-Amornthum","year":"2020","unstructured":"Akara-Amornthum, P., Lomphithak, T., Choksi, S., Tohtong, R. & Jitkaew, S. Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-\u03b1 and chemotherapeutic gemcitabine-induced necroptosis. PLoS One  15 (1), e0227454 (2020).","journal-title":"PLoS One"},{"issue":"1","key":"90997_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12964-020-00661-3","volume":"18","author":"T Lomphithak","year":"2020","unstructured":"Lomphithak, T. et al. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell. Commun. Signal. 18 (1), 161 (2020).","journal-title":"Cell. Commun. Signal."},{"key":"90997_CR31","doi-asserted-by":"crossref","unstructured":"Lomphithak, T., Jaikla, P., Sae-Fung, A., Sonkaew, S. & Jitkaew, S. Natural flavonoids quercetin and kaempferol targeting G2\/M cell cycle-related genes and synergize with Smac mimetic LCL-161 to induce necroptosis in cholangiocarcinoma cells. Nutrients 15 (14). (2023).","DOI":"10.3390\/nu15143090"},{"key":"90997_CR32","doi-asserted-by":"publisher","first-page":"1021632","DOI":"10.3389\/fonc.2022.1021632","volume":"12","author":"S Prasopporn","year":"2022","unstructured":"Prasopporn, S. et al. Combining the SMAC mimetic LCL161 with gemcitabine plus cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front. Oncol. 12, 1021632 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"90997_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2), 440\u2013446 (2010).","journal-title":"Cancer Res."},{"issue":"4","key":"90997_CR34","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.3892\/ol.2017.6736","volume":"14","author":"YS Shan","year":"2017","unstructured":"Shan, Y. S. et al. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncol. Lett. 14 (4), 4517\u20134526 (2017).","journal-title":"Oncol. Lett."},{"issue":"9","key":"90997_CR35","first-page":"1634","volume":"57","author":"S Gansauge","year":"1997","unstructured":"Gansauge, S. et al. Overexpression of Cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57 (9), 1634\u20131637 (1997).","journal-title":"Cancer Res."},{"key":"90997_CR36","doi-asserted-by":"publisher","first-page":"144283","DOI":"10.1016\/j.gene.2019.144283","volume":"728","author":"M Moradi Binabaj","year":"2020","unstructured":"Moradi Binabaj, M. et al. The prognostic value of Cyclin D1 expression in the survival of cancer patients: A meta-analysis. Gene 728, 144283 (2020).","journal-title":"Gene"},{"key":"90997_CR37","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill, M. & Schmidt, M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther. Adv. Med. Oncol. 10, 1758835918793326 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"90997_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/app11010335","volume":"11","author":"Y-C Chang","year":"2021","unstructured":"Chang, Y-C. & Cheung, C. H. A. An updated review of Smac mimetics, LCL161, Birinapant, and GDC-0152 in cancer treatment. Appl. Sci. 11 (1), 335 (2021).","journal-title":"Appl. Sci."},{"issue":"12","key":"90997_CR39","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi, C. R. et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One  9 (12), e115383 (2014).","journal-title":"PLoS One"},{"issue":"11","key":"90997_CR40","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar, F. et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell. Rep. 18 (11), 2780\u20132794 (2017).","journal-title":"Cell. Rep."},{"key":"90997_CR41","doi-asserted-by":"crossref","unstructured":"Stanciu, I. M. et al. Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-metastatic breast cancer-a review of the literature. Diagn. (Basel) 13(5). (2023).","DOI":"10.3390\/diagnostics13050987"},{"issue":"1","key":"90997_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","volume":"25","author":"X Song","year":"2019","unstructured":"Song, X. et al. Combined CDK4\/6 and Pan-mTOR Inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin. Cancer Res. 25 (1), 403\u2013413 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"90997_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao, J. P. The regulation of Cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer  6 (1), 24 (2007).","journal-title":"Mol. Cancer"},{"issue":"1","key":"90997_CR44","doi-asserted-by":"publisher","first-page":"18489","DOI":"10.1038\/s41598-020-75578-5","volume":"10","author":"H Saqub","year":"2020","unstructured":"Saqub, H. et al. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2\/5\/9. Sci. Rep. 10 (1), 18489 (2020).","journal-title":"Sci. Rep."},{"issue":"4","key":"90997_CR45","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 Inhibition. Cancer Cell 37 (4), 514\u2013529 (2020).","journal-title":"Cancer Cell."},{"issue":"1","key":"90997_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt, A. C. & Goel, S. Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 24 (1), 17 (2022).","journal-title":"Breast Cancer Res."},{"key":"90997_CR47","doi-asserted-by":"publisher","first-page":"113676","DOI":"10.1016\/j.bcp.2019.113676","volume":"170","author":"M Bonelli","year":"2019","unstructured":"Bonelli, M., La Monica, S., Fumarola, C. & Alfieri, R. Multiple effects of CDK4\/6 Inhibition in cancer: from cell cycle arrest to Immunomodulation. Biochem. Pharmacol. 170, 113676 (2019).","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"90997_CR48","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.3390\/cancers15164066","volume":"15","author":"AM Elshazly","year":"2023","unstructured":"Elshazly, A. M. et al. BRD4 Inhibition as a strategy to prolong the response to standard of care in Estrogen receptor-positive breast cancer. Cancers 15 (16), 4066 (2023).","journal-title":"Cancers"},{"key":"90997_CR49","doi-asserted-by":"publisher","first-page":"966441","DOI":"10.3389\/fonc.2022.966441","volume":"12","author":"RM Finnegan","year":"2022","unstructured":"Finnegan, R. M. et al. The BET inhibitor\/degrader ARV-825 prolongs the growth arrest response to Fulvestrant\u2009+\u2009Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Front. Oncol. 12, 966441 (2022).","journal-title":"Front. Oncol."},{"key":"90997_CR50","doi-asserted-by":"publisher","first-page":"891580","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra, G. L. et al. CDK4\/6 inhibitors in combination therapies: better in company than alone: A mini review. Front. Oncol. 12, 891580 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"90997_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.onc.1206056","volume":"22","author":"M Bentires-Alj","year":"2003","unstructured":"Bentires-Alj, M. et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22 (1), 90\u201397 (2003).","journal-title":"Oncogene"},{"issue":"49","key":"90997_CR52","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","volume":"18","author":"HL Pahl","year":"1999","unstructured":"Pahl, H. L. Activators and target genes of Rel\/NF-\u03baB transcription factors. Oncogene 18 (49), 6853\u20136866 (1999).","journal-title":"Oncogene"},{"issue":"4","key":"90997_CR53","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cellsig.2011.12.006","volume":"24","author":"A Salminen","year":"2012","unstructured":"Salminen, A., Kauppinen, A. & Kaarniranta, K. Emerging role of NF-\u03baB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell. Signal. 24 (4), 835\u2013845 (2012).","journal-title":"Cell. Signal."},{"issue":"6","key":"90997_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer  22 (6), 340\u2013355 (2022).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"90997_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2018.12.012","volume":"73","author":"SJ Kim","year":"2019","unstructured":"Kim, S. J., Asfaha, S. & Dick, F. A. CDK4 inhibitors thwart immunity by inhibiting phospho-RB-NF-\u03baB complexes. Mol. Cell  73 (1), 1\u20132 (2019).","journal-title":"Mol. Cell"},{"issue":"4","key":"90997_CR56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","volume":"131","author":"E Varfolomeev","year":"2007","unstructured":"Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (4), 669\u2013681 (2007).","journal-title":"Cell"},{"issue":"2","key":"90997_CR57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/hep.23729","volume":"52","author":"CD Fingas","year":"2010","unstructured":"Fingas, C. D. et al. A Smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 52 (2), 550\u2013561 (2010).","journal-title":"Hepatology"},{"issue":"10","key":"90997_CR58","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.bbadis.2019.05.017","volume":"1865","author":"W Peilin","year":"2019","unstructured":"Peilin, W. et al. Directed elimination of senescent cells attenuates development of osteoarthritis by Inhibition of c-IAP and XIAP.Mol. Basis Dis.  1865 (10), 2618\u20132632 (2019).","journal-title":"Mol. Basis Disease"},{"key":"90997_CR59","doi-asserted-by":"crossref","unstructured":"Schwarzenbach, C. et al. Targeting c-IAP1, c-IAP2, and Bcl-2 eliminates senescent glioblastoma cells following temozolomide treatment. Cancers (Basel) 13 (14). (2021).","DOI":"10.3390\/cancers13143585"},{"issue":"6","key":"90997_CR60","first-page":"363","volume":"74","author":"G Jin","year":"2019","unstructured":"Jin, G., Liu, Y., Xu, P. & Jin, G. Induction of necroptosis in human breast cancer drug-resistant cells by SMAC analog LCL161 after caspase Inhibition requires RIP3. Pharmazie 74 (6), 363\u2013368 (2019).","journal-title":"Pharmazie"},{"issue":"1","key":"90997_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2016.05.036","volume":"380","author":"S Hannes","year":"2016","unstructured":"Hannes, S., Abhari, B. A. & Fulda, S. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. Cancer Lett. 380 (1), 31\u201338 (2016).","journal-title":"Cancer Lett."},{"issue":"1","key":"90997_CR62","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/mmr.2015.4542","volume":"13","author":"G Jin","year":"2016","unstructured":"Jin, G. et al. Smac mimetic\u2013induced caspase\u2013independent necroptosis requires RIP1 in breast cancer. Mol. Med. Rep. 13 (1), 359\u2013366 (2016).","journal-title":"Mol. Med. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90997-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90997-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T18:36:42Z","timestamp":1740508602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90997-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90997"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90997-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6826"}}